Archive for ‘FDA’

Page 1 of 1112345...10...Last »

Global Disposable Urine Bags Market Growth Forecast Analysis by Manufacturers, Regions, Type and Application to 2021

Global Disposable Urine Bags Market Growth Forecast Analysis by Manufacturers, Regions, Type and Application to 2021

NS

 

The Global Disposable Urine Bags Market research study report is a respected source of information which offers a telescopic view of the current market status. Various key factors are discussed in the report, which will help the buyer in studying the Global Disposable Urine Bags market trends and opportunities. The Global Disposable Urine Bags market is a highly diligent study on competitive landscape analysis, prime manufacturers, marketing strategies analysis, Market Effect Factor Analysis and Consumer Needs by major regions, types, applications in Global market considering the past, current and future state of the Global Disposable Urine Bags industry. The report provides a thorough overview of the Global Disposable Urine Bags Market including definitions, classifications, applications and chain structure.

This Research study focus on these types: –

  • Bed urine collection bags
  • Leg urine collection bags
  • Night bags
  • others

This Research study focus on these applications: –

  • Hospital
  • Home
  • Others

Get More Details of This Meticulous Global Disposable Urine Bags Research Study @ http://www.360marketupdates.com/10408791

This report studies Interferons in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering

  • Bard
  • Teleflex
  • Coloplast A/S
  • Braun Medical Ltd
  • Convatec
  • Apexmed
  • Coopetition Med
  • BICAKCILAR Tibbi
  • Flexicare Medical
  • UROlogic Aps
  • Medline
  • Steris
  • Urocare
  • Coviden
  • Hillside Medical
  • Vygon Vet

 Visit us to Get Sample PDF of report @ http://www.360marketupdates.com/enquiry/request-sample/10408791

Several important areas are covered in this Global Disposable Urine Bags market research report. Some key points among them: –

  1. What Overview Global Disposable Urine Bags Says? This Overview Includes Diligent Analysis of Scope, Types, Application, Sales by region, manufacturers, types and applications
  2. What Is Global Disposable Urine Bags Competition considering Manufacturers, Types and Application? Based on Thorough Research of Key Factors
  3. Who Are Global Disposable Urine Bags Global Key Manufacturers? Along with this survey you also get their Product Information (Type, Application and Specification)
  4. Global Disposable Urine Bags’s Manufacturing Cost Analysis –This Analysis is done by considering these prime elements like Key RAW Materials, Price Trends, Market Concentration Rate of Raw Materials, Proportion of Raw Materials and Labour Cost in Manufacturing Cost Structure
  5. Global Disposable Urine Bags Industrial Chain Analysis
  6. Global Disposable Urine Bags Marketing strategies analysis by
  7. Market Positioning
  8. Pricing and Branding Strategy
  9. Client Targeting
  10. Global Disposable Urine Bags Effect Factor Analysis
  11. Technology Process/Risk Considering Substitute Threat and Technology Progress In Global Disposable Urine Bags Industry
  12. Consumer Needs or What Change Is Observed in Preference of Customer
  13. Political/Economical Change
  14. What is Global Disposable Urine Bags forecast (2016-2021) Considering Sales, Revenue for Regions, Types and Applications?

Topics such as sales and sales revenue overview, production market share by product type, capacity and production overview, import, export, and consumption are covered under the development trend section of the Global Disposable Urine Bags market report.

Lastly, the feasibility analysis of new project investment is done in the report, which consist of a detailed SWOT analysis of the Global Disposable Urine Bags market. Both established and new players in the Global Disposable Urine Bags industry can use this report for complete understanding of the market.

Wish to Customise By Your Requirement? Ask our expert @ http://www.360marketupdates.com/enquiry/pre-order-enquiry/10408791

Some of key Tables and Figures included in this research study: –

  1. Figure Picture of Global Disposable Urine Bags
  2. Figure USA, Europe, China. Southeast Asia, India, Japan Global Disposable Urine Bags Revenue and Growth Rate (2011-2021)
  3. Table Production Base and Market Concentration Rate of Raw Material
  4. Figure Manufacturing Cost Structure of Global Disposable Urine Bags
  5. Figure Manufacturing Process Analysis of Global Disposable Urine Bags
  6. Figure Global Disposable Urine Bags Industrial Chain Analysis
  7. Figure Global Disposable Urine Bags Sales and Growth Rate Forecast (2016-2021)
  8. Figure Global Disposable Urine Bags Revenue and Growth Rate Forecast (2016-2021)
  9. Table Global Disposable Urine Bags Sales Forecast by Regions (2016-2021)
  10. Table Global Disposable Urine Bags Sales Forecast by Type (2016-2021)
  11. Table Global Disposable Urine Bags Sales Forecast by Application (2016-2021)

Price of Report: $ 2900 (Single User Licence)

Want some discount? Ask for it @ http://www.360marketupdates.com/enquiry/request-discount/10408791

Feel Satisfied? Purchase Global Disposable Urine Bags Research Study @ http://www.360marketupdates.com/purchase/10408791

About 360 Market Updates:
360 Market Updates is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments. Know more about us

Contact–
Mr. Ameya Pingaley
360 market Updates
+1 408 520 9750
Email – sales@360marketupdates.com

Full story

ECG Device Market is Anticipated to Register at a Healthy CAGR of 4.1% by 2024

ECG Device Market is Anticipated to Register at a Healthy CAGR of 4.1% by 2024

Male Doctor Writing On Medical Document

 

ECG devices are proving to be more efficient in ECG monitoring due to advancement in technology, allowing healthcare providers to monitor recorded data remotely and data management facilities for better analysis of data. These factors are expected to fuel the growth of global ECG devices market to grow at a CAGR of 4.1% between 2016 and 2024, according to a new report by Persistence Market Research (PMR). The report, titled, “ECG Device Market: Global Industry Analysis and Forecast, 2016-2024”.

ECG devices are experiencing a paradigm technological shift from resting ECG systems to portable Holter monitoring systems, owing to their advantages of patient mobility, low prices and longer duration of patient monitoring.

PMR’s report offers market forecast and analysis on global ECG device market, segmenting the market on the basis of product, end-user, and region. The report segments the global ECG device market into five key regions, North America, Latin America, Europe, Middle East and Africa (MEA) and Asia Pacific (APAC).  According to the PMR’s regional analysis, North America (U.S. and Canada) is the most lucrative market for ECG devices globally. This region holds highest market share over the forecast period (2016-2024) and is expected to exhibit slow growth rate. The Asia Pacific is expected to be the fastest-growing region for ECG devices owing to its increasing incidence rate of cardiovascular diseases and high population. APAC is estimated to hold nearly 27.3 % revenue share by the end of 2016 in the ECG device market. MEA region is also expected to grow significantly over the forecast period owing to its high public healthcare expenditure and government funding. This region is expected to grow at CAGR of 4.5% over the forecast period.

On the basis of product, PMR has segment the ECG device market into ECG resting system, ECG Holter monitoring system, ECG stress testing system and cardiopulmonary stress testing system segments. ECG Holter monitoring system segment is expected to dominate the market through the forecast period and is anticipated to be the most lucrative segment. Due to the high adoption rate of ECG Holter monitoring devices globally this segment is expected to witness high incremental opportunity.

On the basis of the end user, the ECG device market has been segmented into hospitals, diagnostic centers, clinics and ambulatory surgical centers (ASCs). PMR estimates that hospitals segment accounts for highest revenue share in the end user segment of ECG device market and is expected to witness the fastest growth over the forecast period. Factors like increasing number of private hospitals in emerging countries and government funding for better infrastructure is expected to boost revenue share from hospitals segment for ECG device market. Diagnostic centers segment is also expected to gain significant growth during the forecast period due to better diagnostic facilities and ease of access.

The report discusses several factors affecting the ECG device market like increment in healthcare expenditure, key strategies of the participant companies, reimbursement policies, and regulations.

Request to view Table of Content @ http://www.persistencemarketresearch.com/market-research/ecg-device-market/toc

Some key market participants included in the PMR’s ECG device market include GE Healthcare, Koninklijke Philips N.V, Welch Allyn (Hill-rom company, Inc.), Schiller AG, Fukuda Denshi Co. Ltd., Nihon Kohden Corporation, Mortara Instrument, Inc., Spacelabs Healthcare, Inc.

To Purchase Single User License @ http://www.persistencemarketresearch.com/checkout/3244

About Us

Persistence Market Research (PMR) is a full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.

PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.

Contact

Persistence Market Research

305 Broadway

7th Floor, New York City,

NY 10007, United States

USA – Canada Toll Free: +1 800-961-0353

Email: sales@persistencemarketresearch.com

media@persistencemarketresearch.com

Web: http://www.persistencemarketresearch.com

Full story

Weight Loss and Obesity Management Market: In-depth market segmentation by 2025

Weight Loss and Obesity Management Market: In-depth market segmentation by 2025

Future-Market-Insights190

 

The weight loss and obesity management market includes products, services and therapies for reducing or managing weight in overweight and obese patients. According to the World Health Organization (WHO) definition, body mass index (BMI) greater than or equal to 25 is termed as overweight, while BMI greater than or equal to 30 is termed as obesity. Rising global burden of obesity and overweight is driving the need for preventive care. The global weight loss and obesity management market is analyzed by three major segments namely diets, services and fitness and surgical equipment.

The diets segment includes global market for food, beverage and supplement. The weight loss food market includes meal replacement, low-calories desserts, sugar-free confectionaries, low-calorie meals and organic foods. While the weight loss beverage market is classified into low-calorie beverages, herbal/green tea, slimming water or natural mineral salt drinks and other low calorie beverages. The demand for herbal/green tea is growing rapidly in Asia, which provides large untapped opportunities for key players in this region. The weight loss supplements market includes products such as protein, fiber, green tea extract and conjugated linoleic acid (CLA). These supplements provide only with the required amount of nutrients to the body, thus maintaining the nutritional levels in the body. Change in eating habits is a very effective treatment method for managing weight lossThe weight loss fitness and surgical equipment market is segmented based on the fitness equipment and surgical equipment available commercially. The fitness equipment market includes products such as cardiovascular training equipment, strength training equipment, body composition analyzers and fitness monitoring equipment. Besides, cardiovascular training equipment such as treadmills, stationary cycles, elliptical trainers, rowing machines, and stair steppers are utilized in fitness centers to guide patients for healthy living by managing their body weight.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-411

Based on the types of surgical equipment, the global weight loss and obesity management market is classified in two broad categories as minimally invasive surgical equipment and non-invasive surgical equipment. Minimally invasive surgical equipment includes bariatric surgery and liposuction procedural equipment, which are the preferred surgical methods in severe obesity. In addition, evolution of non-invasive surgical equipment such as intragastric balloon system, StomaphyX, cold laser shaping, and cryolipolysis have made the weight loss procedures safe and effective.

The weight loss and obesity management market is also classified based on the services as fitness centers, slimming centers, diet nutrition and psychological consulting services. Advent of new centers for the weight loss and obesity management services drives the demand for fitness equipment and supplements. Rising health consciousness has led to increase in the visits to fitness centers, thus leading to a growth of the weight loss and obesity management market.

Some of the major factors driving the growth of the weight loss and obesity management market include rising incidence of obesity, increasing number of lifestyle diseases such as diabetes, cardiovascular diseases and rising disposable incomes. Furthermore, initiatives by government and non-profit organizations to increase awareness about health and fitness are driving the demand for food, beverages and supplements. Moreover, according to WHO, obesity and overweight are the fifth leading risk of deaths globally. Statistics from Mexico Bariatric Center shows that globally, U.S. has the highest prevalence of obesity followed by India and China. Besides, Japan and Australia are also among the top 10 countries for the prevalence of obesity. This would lead to a rapid pace of growth in the Asia-Pacific region.

Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-411

Some of the key players in the global weight loss and obesity management market include Atkins Nutritionals, Inc., Weight Watchers International, Inc., Life Time Fitness, Inc., Golds Gym International, Inc, Brunswick Corporation, Precor, Inc., Ethicon Endo-surgery, Inc. and Allergan, Inc.

Full story

Covidien Endo GIA Reinforced Stapling Reload Technology Cleared by FDA

Covidien Endo GIA Reinforced Stapling Reload Technology Cleared by  FDA

                 Tri Staple Covidien Endo GIA Reinforced Reload with Tri Staple Technology Cleared by FDA

 

Covidien received  FDA 510(k) clearance for the Endo  GIA Reinforced Reload with Tri-Staple technology. The new stapler features a layer of NEOVEIL, a polymer porous felt developed by GUNZE (Osaka, Japan), as a buttressing material.

The layer of NEOVEIL provides support to the tissue that’s being stapled or resected, particularly benefiting fragile tissue such as in the lungs that may otherwise sustain damage during  the procedure.

From the announcement:

All Covidien Endo GIA reloads with Tri-Staple technology are designed to work in the  harmony with the  natural properties of the tissue to optimize performance during stapling.

The advanced polymer buttressing material is a version of NEOVEIL® felt, developed by GUNZE Ltd, which has been in clinical use in the Japanese market for more than 20 years.

In January, Covidien received Shonin approval from the Japanese Ministry of Health,  and Welfare for the Endo GIA Reinforced Reload with Tri-Staple technology. Covidienexpects to offer the new product in the U.S. and Japanese markets in the coming months..

Press release: Covidien Receives U.S. FDA 510(k) Clearance for Reinforced Stapling Reload Technology…

Full story

CAREFUSION RECEIVES 510(k) CLEARANCE FOR VERTEBRAL AUGMENTATION SYSTEM

CAREFUSION RECEIVES 510(k) CLEARANCE FOR VERTEBRAL AUGMENTATION SYSTEM

AVAflex® Vertebral Balloon System Enables Targeted Balloon Placement

Jan 30, 2014


SAN DIEGO, Jan. 30, 2014
 – CareFusion (NYSE:CFN), a leading global medical technology company, today announced it recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new AVAflex® Vertebral Balloon System.

The new system is the latest innovation in CareFusion’s AVAmax®Advanced Vertebral Augmentation portfolio. The focus of these products is to provide a minimally invasive solution to treat vertebral compression fractures, while also promoting safety for the patient, physician and staff. The AVAflex Vertebral Balloon System combines the unique features of the AVAflex Curved Vertebral Augmentation Needle and the AVAmax Vertebral Balloon to enable targeted balloon placement across the midline of the vertebral body, followed by targeted cement placement for optimal fill through a single pedicle.

The AVAflex Vertebral Balloon System is in limited commercial release in multiple hospitals across the U.S.

“The ability to steer a balloon through a unipedicular approach cannot be overstated in its simplicity and efficiency,” said Dr. Michael Verdolin of Verdolin Pain Specialists in Chula Vista, Calif. after using the product. “The procedure was faster, with less patient discomfort.”

Dr. Allan Brook, an interventional radiologist with Montefiore Medical Center in Bronx, N.Y. and the first physician to use the new device on the East Coast, said “The unipedicular approach offers a less risky approach to the midline of a vertebral body. Having another tool that places the cavity in the desired location can improve the effectiveness of vertebral augmentation in less time and with less radiation.”

Another physician using the device in limited commercial release, Dr. Langham Gleason, a neurosurgeon with the South Texas Brain and Spine Center in Corpus Christi, Texas, said “The AVAflex Vertebral Balloon System works extremely well to allow bilateral fracture reduction using a unilateral approach. I suspect that placement of bilateral vertebral cannulas will largely fade away in the future.”

CareFusion expects a full commercial launch of the AVAflex Vertebral Balloon System in Spring 2014
.

Source : http://media.carefusion.com/index.php?s=32344&item=136851

Full story

An artificial pancreas invented can bring an end to the misery of daily injections for diabetics

An artificial pancreas invented can bring an end to the misery of daily injections for diabetics

It’s the first device approved by the FDA that detects dropping sugar levels and shuts off regular insulin delivery for Type 1 diabetics, just like a real pancreas is one of  the Best Inventions of the Year 2013 .Too much insulin, which is common at night, can lead to life-threatening diabetic comas.

An artificial pancreas invented by a De Montfort University (DMU) professor could have its first human trials within two years.

Professor Joan Taylor’s creation ensures patients will no longer have to endure injections of insulin every day.

Instead, a device will be surgically implanted into the body and able to release a precise amount of insulin into the bloodstream. Supplies would be topped up every two weeks.

Human trials are due to begin in 2016 with the first implants taking place on the NHS within a decade – news which has featured prominently in the national press with articles in the Daily Express and the Daily Mail among others.

Professor of Pharmacy at DMU, Joan Taylor, said: “The device will not only remove the need to manually inject insulin, but will also ensure that perfect doses are administrated each and every time. By controlling blood glucose so effectively, we should be able to help reduce related health problems.

“We are extremely close to embarking on clinical trials. Diabetes is costing society more than £1million an hour in treatment, and much of that is spent on treating complications.”

The implant contains a reservoir of insulin kept in place by a special gel barrier. When glucose levels in the body rise, the gel liquefies and releases the insulin into the body, mimicking the normal pancreas.

As the insulin lowers the glucose levels, the gel reacts by hardening again and preserving the reservoir. It would eliminate the need for diabetics to inject insulin up to four times a day.

The artificial pancreas will help all Type 1 insulin-dependent diabetics and some suffering Type 2 who need daily injections.

Professor Taylor has spent 20 years developing the device, which requires no electronics. This means the risk of rejection by the body is minimised.

Until now, the project has had funding of £1 million from the NHS, the Lachesis Fund – which invests in research in the university – the charity Edith Murphy Foundation and private backers. Professor Taylor is now seeking a similar amount to refine the product.

“This device is cheap and simple to use,” added Professor Taylor. “It has the potential to bring an end to the misery of daily injections for diabetics.”

- SOURCE: http://www.dmu.ac.uk/research/research-news/2014/january/human-trials-in-two-years-for-artificial-pancreas-invention.aspx#sthash.42N8lBYF.dpuf

Full story

Option Elite Retrievable Vena Cava Filter Receives FDA Approval for a New Over-The-Wire Delivery Technique

Option Elite  Retrievable  Vena Cava  Filter  Receives  FDA Approval for a New Over-The-Wire Delivery Technique

                                                                      OptionELITE Option Elite Retrievable Vena Cava Filter Gains FDA Approval for a New Over The Wire Delivery Technique

Argon Medical (plano,TX), has received FDA 510(k)   clearance to market a new over- the-wire delivery technique for the Option Elite Retrievable the Vena Cava Filter. Physicians can now deliver the filter by using a guidewire, which improves the safety of the procedure and also allows for  better  centering of the filter within the inferior vena cava.

The Option  Elite Vena cava Filter,which was designed by REX MEDICAL,is the first retrievable vena cava filter approved for over-the -wire delivery.The nitinol filter can be guided through the jugular or femoral access using a 6.5 Fr catheter that employs  a color coded filter introduction cartridge.The Option Elite filter also features  a unique filter apex design and retention anchor system that allow for the efficient clot capture.It can be used to capture emboli in IVCs with diameters ranging from 30mm to 32 mm.The kink resistant catheter uses curved pushers that allow for more accurate  placement of the filter.

Argon Medical is set to  launch the Option ELITE filter with the new over-the-wire delivery technique at the 26th Annual International Symposium of Endovascular Therapy this week in Miami, Florida.

Press release: Option™ELITE Retrievable Vena Cava Filter Receives FDA Clearance for a New Over-The-Wire Delivery Technique and Enters New Markets Worldwide….

Full story

Acuson Freestyle, a Wireless Interventional Ultrasound System from Siemens

Acuson Freestyle, a Wireless Interventional Ultrasound System from Siemens

Acuson Freestyle, a Wireless Interventional Ultrasound System from Siemens

Siemens has entered into an agreement to acquire Invensys Rail, the rail automation business of Invensys for approximately €2.2 billion (£1.742 billion). At the same time, the company plans to divest its baggage handling, postal and parcel sorting activities. Both planned transactions are part of the recently launched “Siemens 2014″ company program, which amongst others, is aimed at strengthening the company’s core activities. With revenues of approximately £800 million, Invensys Rail is a leading software based rail signaling and control company. The acquisition will expand Siemens’ presence in the growing global rail automation market. “Today’s moves are important measures to focus our core activities. We are exiting a non-core business with limited synergy potential while strengthening a resilient and high return business by combining two organizations with similar cultures and attractive synergy potential. The combined business will ensure profitable growth opportunities worldwide for the Siemens Infrastructure & Cities Sector,” said Roland Busch, CEO of Siemens Infrastructure & Cities. The transaction is subject to Invensys shareholder approval and regulatory clearances.

The planned divestment of the baggage handling, postal and parcel sorting activities will further focus the activities of the Siemens Infrastructure & Cities Sector. While the company is one of the leading players in postal automation, parcel and baggage handling systems with a global presence and an installed base around the world, there are few synergies with other Siemens Divisions due to the high mechanical content. It is a highly specialized niche business, dominated by mid-sized companies. The mid-single-digit profit margin business with revenue of approximately €900 million and around 3,600 employees shall be sold.

Invensys Rail shall be integrated into Siemens’ Rail Automation business in the Mobility and Logistics Division of the Infrastructure & Cities Sector. “With the addition of Invensys Rail we are in an excellent position to offer best-in-class solutions and technology to rail operators worldwide. The combination of two excellent organizations will create a truly global player in the Rail Automation business,” said Sami Atiya, CEO of Siemens’ Mobility and Logistics Division.

Invensys Rail has a strong footprint and a well established reputation with customers in the UK, Spain, the U.S. and Australia which will extend Siemens’ Rail Automation existing presence in countries such as Germany, Austria, Switzerland as well as China and India. In recent years, Invensys Rail has also successfully expanded its business into fast-growing emerging regions. The combined Invensys Rail and Siemens product portfolio will offer a full range of automation and optimization products, solutions and services, covering all customer segments.

The growth outlook of the global rail automation market is driven by increasing urbanization and the demand for enhanced mobility including new and extended mass transit and commuter systems. Overall the rail sector benefits also from trends such as energy efficiency, environmental factors, liberalization, deregulation and low-cost transportation requirements.

Significant synergy potential is expected from the combination of territories and technologies together with cost savings in procurement, portfolio, engineering and SG&A. Synergies of over €100 million are expected, to be fully achieved by 2018.

In its last fiscal year ending March 2012, Invensys Rail generated revenues of £775 million and operating profit before interest and taxes of £116 million, representing a 15% margin. Order intake (excluding framework agreements) was £991 million, including major awards in new countries such as Saudi Arabia and Turkey. As of March 2012, Invensys Rail’s total order book was £1,202 million and it currently employs around 3,200 employees.

Siemens provides integrated mobility solutions and already has a significant and established rail automation business with revenues of €1.4 billion, employing around 6,500 employees. Invensys Rail shall be integrated into this business, which is headquartered in Berlin, Germany. Siemens and Invensys Rail managers will form the new management team and Invensys Rail’s local expertise and relationships will be retained. The new constellation will combine the regional strengths of both organizations for the benefit of its customers.

The transaction is subject to Invensys shareholder approval which is expected to be voted on at a General Meeting planned for December 2012. Furthermore, consent by Invensys’ lenders, the UK pension regulator and anti-trust authorities is required. Overall Siemens will not take on any significant pension liabilities with the transaction. Siemens expects the transaction to close in the second quarter of calendar year 2013.

Siemens AG (Berlin and Munich) is a global powerhouse in electronics and electrical engineering, operating in the fields of industry, energy and healthcare as well as providing infrastructure solutions, primarily for cities and metropolitan areas. For over 165 years, Siemens has stood for technological excellence, innovation, quality, reliability and internationality. The company is the world’s largest provider of environmental technologies. Around 40 percent of its total revenue stems from green products and solutions. In fiscal 2012, which ended on September 30, 2012, revenue from continuing operations was €78.3 billion and income from continuing operations was €5.2 billion. At the end of September 2012, Siemens had around 370,000 employees worldwide on the basis of continuing operations. Further information is available on the Internet at: http://www.siemens.com.

This document contains statements related to our future business and financial performance and future events or developments involving Siemens that may constitute forward-looking statements. These statements may be identified by words such as “expects,” “looks forward to,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “will,” “project” or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to stockholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Siemens’ management, and are, therefore, subject to certain risks and uncertainties. A variety of factors, many of which are beyond Siemens’ control, affect Siemens’ operations, performance, business strategy and results and could cause the actual results, performance or achievements of Siemens to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements or anticipated on the basis of historical trends. These factors include in particular, but are not limited to, the matters described in Item 3: Risk factors of our most recent annual report on Form 20-F filed with the SEC, in the chapter “Risks” of our most recent annual report prepared in accordance with the German Commercial Code, and in the chapter “Report on risks and opportunities” of our most recent interim report.

Further information about risks and uncertainties affecting Siemens is included throughout our most recent annual and interim reports, as well as our most recent earnings release, which are available on the Siemens website, www.siemens.com, and throughout our most recent annual report on Form 20-F and in our other filings with the SEC, which are available on the Siemens website, www.siemens.com, and on the SEC’s website, www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results, performance or achievements of Siemens may vary materially from those described in the relevant forward-looking statement as being expected, anticipated, intended, planned, believed, sought, estimated or projected. Siemens neither intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.

Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

Using ultrasound during interventional procedures can be a cumbersome proposition due to the heavy cables linking the transducer to the main device unit. Clinicians often have to reposition the ultrasound to gain better access to the patient, potentially overcoming obstacles like other cables, staff, and their feet. Siemens unveiled a new ultrasound system that uses a wireless transducer that eliminates the cable problem and offers a more natural approach. Here’s a quick demo of the Acuson Freestyle that we were able to capture from the floor of RSNA 2012:

Source : https://www.siemens.com/press/en/pressrelease/?press=/en/pressrelease/2012/healthcare/clinical-products/hcp201211006.htm

Full story

Latest X Prize Foundation Competition Offers $10 Million For a Tricorder

Latest X Prize Foundation Competition Offers $10 Million For a Tricorder

Latest X Prize Foundation Competition Offers $10 Million For a Tricorder

The X PRIZE Foundation and Qualcomm Join Forces to Develop a Competition to Enhance Integrated Digital Health

PLAYA VISTA, CA–(Marketwire – May 10, 2011) – The X PRIZE Foundation, the leading nonprofit organization solving the world’s Grand Challenges of our time by creating and managing large-scale, global incentivized competitions, today announced a collaboration with Qualcomm Incorporated to design the Tricorder X PRIZE, a $10 million prize to develop a mobile solution that can diagnose patients better than or equal to a panel of board certified physicians. The X PRIZE Foundation and Qualcomm seeks to achieve this by combining advancements in expert systems and medical point of care data such as wireless sensors, advancements in medical imaging and microfluidics.

The Tricorder X PRIZE aims to incentivize consumer empowerment in healthcare by extending the reach of health information and services to more people. This prize will bring understandable, easily accessible health information and metrics to consumers on their mobile devices, pointing them to earlier actions for care.

“For years, Qualcomm has been transforming lives by connecting people through incredible technologies,” said Dr. Peter Diamandis, Chairman and CEO of the X PRIZE Foundation. “The X PRIZE Foundation is honored to work with Qualcomm to positively affect health consumers by developing a prize that will revolutionize consumer’s access to health data and information.”

The collaboration between the X PRIZE Foundation and Qualcomm will bring together experts in technology usability, wireless sensors, cloud computing and mobile health to accelerate the convergence of these fields. The winning tool will enable consumers in any location to quickly and effectively assess health conditions, determine if they need professional help and answer the question, “What do I do next?”

“Qualcomm strives to provide a means to see choices, make decisions and get the right care faster and more conveniently. We believe this is a fundamental step in helping people become true ‘Health Consumers’ who can have as much say in assessing and accessing healthcare as they would any other service or product,” said Don Jones, Vice President of Wireless Health Strategy and Market Development at Qualcomm Labs. “Qualcomm believes the value of this X PRIZE is also in changing the cost structure and focus of healthcare. By having consumers take the initial actions to obtain health assessment data, the use and the quality of physicians’ time is improved.”

Eugene Wesley “Rod” Roddenberry, Jr., son of Star Trek creator, Gene Roddenberry, commented, “It is great to see two amazing organizations — the X PRIZE Foundation and Qualcomm — bring the technology of Star Trek to life and make the Tricorder a reality for people everywhere.”

The X PRIZE Foundation will be collaborating with industry experts and advisors to complete the Tricorder X PRIZE design in 2011. It expects to launch the competition in early 2012.

ABOUT THE X PRIZE FOUNDATION

Founded in 1995, the X PRIZE Foundation is the leading nonprofit organization solving the world’s Grand Challenges by creating and managing large-scale, high-profile, incentivized prize competitions that stimulate investment in research and development worth far more than the prize itself. The organization motivates and inspires brilliant innovators from all disciplines to leverage their intellectual and financial capital for the benefit of humanity. The X PRIZE Foundation conducts competitions in four Prize Groups: Education & Global Development; Energy & Environment; Life Sciences; and Exploration (Ocean and Deep Space). Prizes won include the $10 million Ansari X PRIZE for private, suborbital space flight; the $10 million Progressive Insurance Automotive X PRIZE for creating safe, affordable, production-capable vehicles that exceed 100 MPG energy equivalent (MPGe); and the $2 million Northrop Grumman Lunar Lander X PRIZE CHALLENGE for advanced rocket development. Active prizes include the $30 million Google Lunar X PRIZE, the $10 million Archon Genomics X PRIZE, and the $1.4 million Wendy Schmidt Oil Cleanup X CHALLENGE. For more information, visit www.xprize.org.

X Prize Foundation, the non-profit organization that has awarded millions of dollars for sub-orbital spacecraft and ultra-efficient automobiles, has announced a new competition in collaboration with Qualcomm. The competition (which is actually called the Tricorder X PRIZE) will award a $10 million prize to the developer of a mobile solution to diagnose patients as well, or better than, a panel of physicians.

According to the X Prize Foundation and Qualcomm, the winning design should integrate the latest in wireless sensors, medical imaging, microfluidics, and cloud computing. It should allow a user to assess health conditions anywhere, determine if they need further professional help, and overall answer the question, “What do I do next?”

The details of the competition are currently being decided, and the competition is expected to launch in early 2012, so get your creative juices flowing and help make yet another fictional piece of Star Trek technology become reality!

Source : http://www.marketwire.com/press-release/x-prize-foundation-qualcomm-join-forces-develop-competition-enhance-integrated-digital-1512263.htm

Full story

Barco’s New Breast Tomosynthesis Monitor

Barco’s New Breast Tomosynthesis Monitor

Barco’s New Breast Tomosynthesis Monitor

Visualization specialist Barco has launched the Mammo Tomosynthesis 5MP, the first display system that has been cleared by the US Food and Drug Administration (FDA) for breast tomosynthesis. The display comes with some groundbreaking technologies specifically developed for multi-modality mammography.

“Breast tomosynthesis provides radiologists with three-dimensional images of the breast for better lesion visibility. These multi-frame images give rise to a need for solutions to optimize reading and interpretation. That’s why Barco developed the Mammo Tomosynthesis 5MP, a display system for digital breast imaging”, says Albert Xthona, Product Manager at Barco Healthcare.

“Its unique technologies for brighter and faster tomosynthesis visualization enable detection of the smallest details, providing radiologists with a new degree of diagnostic confidence and performance. With the Mammo Tomosynthesis 5MP, images are displayed more efficiently and more clearly so the radiologist can make the most effective diagnosis”, Xthona concludes.

Precise results

The Mammo Tomosynthesis 5MP efficiently displays high-quality multi-modality images. Barco’s proprietary RapidFrame™ technology speeds pixel refresh when reviewing multi-frame image sequences such as tomosynthesis or breast MRI, eliminating blurring or ghosting. Combined with Barco’s patented Per Pixel Uniformity™ (PPU) to remove disturbing screen noise, the display renders mammograms with the best image quality, helping radiologists make accurate diagnoses while speeding up their workflow.

Equipped with the powerful DuraLight Nova™ backlight, the Mammo Tomosynthesis display offers twice the calibrated brightness (1,000 cd/m²) of conventional displays, while more than doubling the lamp lifetime (50,000 hours). This luminance enables radiologists to see fine details in dense breast tissue and renders near skin-line details more clearly. The display also provides an I-Luminate™ ‘hot light’ button for extra brightness, which can reveal subtle details, even in dark areas.

Comfortable reading

The Mammo Tomosynthesis 5MP comes with an adjustable dual-head stand and allows users to angle the displays to their preferred position for optimum viewing. Additionally, the display can be viewed from a wide angle, without sacrificing contrast or black level. Images can now be read from any seat at the reading station, allowing radiologists to discuss the images with colleagues in the room or use them for educational purposes.

The display system’s intrinsic brightness reduces eye fatigue and enables reading in a more pleasant ambient room light, preserving visibility of low-contrast details. It also includes the integrated I-Guard™ sensor which automatically checks contrast and luminance. This provides radiologists with an optimal work environment, boosting diagnostic performance and productivity.

Guaranteed compliance

To ensure long-lasting image quality and high-grade Quality Assurance, Barco’s Mammo Tomosynthesis 5MP is bundled with MediCal QAWeb, an innovative web-based tool for automated and worry-free calibration. Together with I-Guard, the system guarantees consistent DICOM accuracy and uptime of all displays throughout the facility to ensure a consistent diagnostic outcome.

The standard of care

The Mammo Tomosynthesis 5MP is covered by a 5-year warranty and demonstrates that precision and productivity can go hand in hand. Equipped with the ultra-fast 10-bit MXRT display controller and technologies to enable consistent cost-effective workflow, the display for multi-frame mammography offers a high return on investment and the best standard of care.

Barco at SBI 2011

Barco’s Mammo Tomosynthesis 5MP will be showcased at SBI 2011 – booth #200 – in San Antonio, USA, from 18 to 20 May, 2011. Commercial availability is planned for the third quarter of 2011.

About Barco

Barco, a global technology company, designs and develops visualization products for a variety of selected professional markets. Barco has its own facilities for Sales & Marketing, Customer Support, R&D and Manufacturing in Europe, North America and Asia Pacific. Barco (NYSE Euronext Brussels: BAR) is active in more than 90 countries with about 3,500 employees worldwide. Barco posted sales of 897 million euro in 2010.

Optimized for digital breast tomosynthesis

Barco’s Mammo Tomosynthesis 5MP has been developed to optimize reading and interpretation of digital breast tomosynthesis, a groundbreaking imaging modality that significantly improves accuracy of breast cancer detection. Its unique technologies for tomosynthesis visualization increase conspicuity of the smallest details, providing radiologists with a new degree of diagnostic confidence.

The Mammo Tomosynthesis 5MP is the first display system available for breast tomosynthesis. It is cleared by the US Food and Drug Administration (FDA) for use in standard and multi-frame digital mammography as well as breast tomosynthesis.

Quick readings, exceptional results

The Mammo Tomosynthesis 5MP ensures instant delivery of images without motion blur, increasing correct diagnosis and swift workflow.

Bright images, more details

Featuring twice the brightness of conventional systems and lasting twice as long, the Mammo Tomosynthesis 5MP offers unrivalled image precision and visibility of the most subtle details.

Less noise, improved accuracy

Screen noise often hides subtle details. That’s why the Mammo Tomosynthesis 5MP ensures pixel-perfect images without disturbing screen noise, offering clearer visibility of differences in tissue density.

Guaranteed compliance, diagnostic confidence

Automated checks of contrast and luminance, in combination with an online calibration service, result in an optimal working environment and worry-free readings.

Barco has just received the first ever FDA approval for a computer monitor to be used for viewing breast tomosynthesis imagery. Tomosynthesis involves sequential movie-like playback of images of the breast taken from different angles, so the monitor has to properly render each frame quickly and with precision.

From the product page:

RapidFrame ™: vq34sdff Barcos New Breast Tomosynthesis MonitorRapidFrame technology counteracts motion blur when scrolling through a stack of images due to a high pixel refresh rate.

Per Pixel Uniformity™: PPU measures and adjusts the luminance of each pixel, making every pixel permanently DICOM compliant.

SmoothGray™: SmoothGray generates ultra-precise representations of grayscale images and eliminates quantization artifacts, reducing the overall noise in the images.

DuraLight Nova™: the DuraLight Nova backlight ensures a diagnostic luminance of 1,000 cd/m². In addition, they last twice as long without increasing power consumption.

I-Luminate™: a push on the ‘hot light’ I-Luminate button will temporarily boost display brightness, allowing inspection of subtle details or comparison of digital exams with film-based priors.

I-Guard™: the integrated I-Guard sensor continually guards and adjusts the luminance output of the display, ensuring continuous compliance with the DICOM standard.

QAWeb: the innovative MediCal QAWeb system is an easy-to-use, web-based tool for automated calibration and Quality Assurance.

Adjustable dual-head stand: the dual-head stand allows users to angle the displays to fit their preferred position for optimum viewing.

Source : http://www.barco.com/en/News/Press-releases/barco-launches-first-display-system-for-breast-tomosynthesis.aspx

Related Posts Plugin for WordPress, Blogger...

Full story

Page 1 of 1112345...10...Last »
Copyright © 2017 Medical Technology & Gadgets Blog MedicalBuy.net. All rights reserved.
Proudly powered by WordPress. Developed by Deluxe Themes